Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO expect revenue of > £9 million (in-line with analysts) for this year, and probably double that in 2017 which would make them profitable. And this is with products that are already on the market and generating sales today (produced just under £2 million in rev last year).
Enough cash to get them to profitability.
Selling cancer product under "compassionate use" today in UK, shortly in US.
CEO say "100's of millions in revenue in the next 5-7 years" (OK, take that one with a grain of salt )
I own some MTP because of their acquisition or DARA. But today I increased my position considerably. I like both the short and long term prospects.
2017 could be their breakout year.
If you're a trader, sell the news. If you're an investor, that call screamed BUY.
I bought.
Sounds extremely encouraging. Debt is largely restructured -- they have no more principal payments until 2019 on one large part of it, and together with the Ginkgo payments expected, they're saving $45 million in H2. They now expect to be cash flow positive in the back half of this year!
Huge turnaround seems to be underway.
I've been looking for some more intelligent analysis on RDHL for a while.. there are very few people on the RHDL board here on iHub (also the Intro is really old), and only a few more over on Yahoo.
IMHO (but I'm not a seasoned biotech investor nor experienced in the bio/medical field), it's a very compelling investment.
I'd welcome anyone else's analysis or research, especially @KarinCA out of respect for her DD and insight over on the CTIX board, and her obvious expertise in biotechs.
Thx to all, and best of luck.
CEO's own summary of the company at the close of his prez at JPM yesterday:
$130 million market cap
Dual Israeli and NASDQA listing (relatively new to NASDAQ)
3 Phase III's underway in US
all 3 are potential blockbusters
several Phase II programs underway
plenty of cash in the bank ($53 million as of Q1)
burn rate of $6-8m/Q
no debt
back by worlds's top healthcare investors
pharma deal in place already
multiple catalysts coming
aiming to become specialty pharma player in the US
Does it get any better than this in biotech investing?
Yes, a peer-reviewed article authored by a reputable third-party is a ringing endorsement of the efficacy of this product. And with the PII results showing good safety and tolerance, I expect the PIII top-line results will be good.
Potential here is huge. I added more today.
A non event? For traders, perhaps. For shareholders, it's fabulous news. I'm delighted. Bought a little more today.
Just read through the court's entire judgement. It's as scathing as the original attack was. A great read.
Below is a list of the section titles alone, from the court's ruling. It's hard to imagine a law firm so incompetent (or dishonest?) as to "fail" at every single one of the claims in their original filing.
Great victory for CTIX shareholders. Greater victory for the investment community overall.
---
Defendants’ Request for Judicial Notice Is Granted in Part, and Plaintiff’s Request Is Denied as Moot
Plaintiff Fails to State a Claim for Securities Fraud
Defendants Are Not Liable for the False Statement in the Future Woman Article
Defendant Ehrlich Adequately Corrected the False Statement Made in Cellceutix’s 2009 Form 10-K
Plaintiff Has Failed to State a Claim Based on Defendants’ Statements Regarding Brilacidin
Plaintiff Has Failed to State a Claim Concerning Brilacidin’s Gram-Negative Coverage
Plaintiff Fails to State a Claim Regarding Brilacidin’s Antibiotic Properties
Plaintiff Fails to State a Claim Based on Defendants’ Statements Regarding Kevetrin
Plaintiff Fails to State a Claim Regarding Defendants’ Representation of p21 as a “Biomarker” in Clinical Trials for Kevetrin
Plaintiff Fails to State a Claim Regarding the Kevetrin Trial Patient’s Outcome
Plaintiff Fails to State a Claim Regarding Defendants’ Failure to Disclose Material Risks
I also added more today, just after the open. H2 should bring good top-line results from 2 trials.
IMO, Addex has a decent possibility of a partnership for Dipraglurant Phase III, expected to start early next year. It would be nice to put that in place before they need to raise more capital. It has FDA OD status, and Phase II results were very positive (no AE's and clear efficacy) and now published in peer-review journals.
If they can get one molecule off the ground, it would help validate their entire allosteric discovery platform, and long-term Addex could be a multi $bn company.
Patience. I was happy to pickup some more on this news, even though I'd expected it and could have bought lower recently. I suspect it may be days or weeks before we see the market's full reaction to the lawsuit dismissal. But I don't expect we'll get back to pre-Mako levels without more news about progress.
Two great new projects have leaked out recently, without the CEO making any formal noise about them. The first is a 12,000 Kromatix panel-clad school in Copenhagen, and another smaller one in Leysins, Switzerland.
http://inhabitat.com/worlds-largest-solar-glass-facade-will-supply-half-the-electricity-for-copenhagen-international-school/emirates-insolaire-kromatix-solar-glass-2/
https://www.instagram.com/p/BF4S9AZG4eA/?taken-by=rafichanbali
Gone are the days where a company's Q-by-Q results or news can move the share price in any controllable fashion. A modern CEO should not concern him/herself with the share price on any horizon under 3-5 years. To do otherwise would be to pander to traders, not "shareholders".
To work for sharholders, a CEO needs to build the company and keep it on sound financial ground. If that's done well, the share price will trend up as well.
CTIX's platform is advancing nicely. In the next few months, the PPS may zigzag like crazy, and it will have zero to do with the Leo's influence. But in 3+ years, the shareprice will have everything to do with Leo's success (or failure) at running this company and advancing their pipeline.
He pretty much has to now, doesn't he? I mean, he hinted rather strongly that his preferred route would be to partner P after Phase II results are back, AND that they had interested parties already, depending on the outcome. So we all want to know if these results qualify as good enough for partnership, and/or want confirmation that this is still his preferred route to market with P.
shareholders just won again. Welcome to the whiplash that is the OTC
Anyone who sold today doesn't meet my definition of "shareholder" anyway, so no shareholders lost today. Quite the opposite -- there is more future value in CTIX shares today than there was yesterday. The trial results were decent. Not outstanding, but strong enough to move forward.
This company has not ever failed either in pre-clinical or clinical trials for any one of their pipeline drugs. That's a stellar record so far. Today's results are more of the same. Share price will always vary from under-valued to over-valued. Long term, however, it will trend with the clinical and commercial successes, all of which are looking very good.
most myopic post of the week
There is simply no way you truly believe the tech works and that there will ever be any "epic" execution with this company. Some of us have been here for dogs years, yourself included.
There is overwhelming proof that P2O NEVER worked anywhere close to as well as JB said it did, except possibly when measured as a straight-line short-lived process using a clean processor and virgin plastic that is worth more as plastic that it was in fuel form EVEN when oil was over $75/barrel.
P2O is a scam. Bordynuik is a crook. Real people lost real money.
Time for everyone to lick their wounds, and go home with whatever money, pride, and integrity they can still salvage after this fiasco.
Another overdue 10Q just filed... nice to see them still catching up. The company never did any PR about the Danish school building, despite it being the first of it's kind in the world. I'm still holding out for a catch-up with all SEC filings followed by a comprehensive commercial update from the CEO. This _should_ be the year their colored panels finally get the limelight they deserve.
Value is all about perception. The CEO works for shareholders, not traders, and as such has a responsibility to build the business and commericalize their drugs. That takes years.
CEO and team have build incredible value, as evidenced by on-going FDA discussions, past non-clinical results, and interim clinical results.
If an eroding share price is proof criminal activity on behalf of the CEO, then a sudden rise in the price would indicate what? An absolution of all guilt?
Spare us the drama, please.
The only thing "predicable" are the remarks from traders when the short-term share price doesn't go in the direction they'd hoped.
Humor us please.. what precisely has CTIX management done that is "criminal" ? TIA
A post by the CEO about a new Swiss project, on LinkedIn.com: https://www.linkedin.com/pulse/watt-beauty-rafic-hanbali?trk=prof-post
A post by the CEO about a new Swiss project, on LinkedIn.com: https://www.linkedin.com/pulse/watt-beauty-rafic-hanbali?trk=prof-post
Yeah, I wouldn't mind a little surprise on the earning side for a change. Great progress with partnerships, IP, and products, but lagging one the whole revenue thing For now....
Possibly indirectly, yes, as SolarEdge's inverters are indeed transformerless and unidirectional. But Tesla + SolarEdge only have a residential offering I believe. The new SunDial 30kW from IPWR will be targeted at C&I sites, as residential typically requires only 4-10kW. That said, sounds like there may be a residential offering in the works.
News: IDEAL POWER INTRODUCES NEW SUNDIAL SOLAR PV STRING INVERTER
http://ir.idealpower.com/press-releases/detail/570/ideal-power-introduces-new-sundial-solar-pv-string-inverter
Nice to see management participating in the PIPE. I'm feeling pretty good about the binary event actually happening.
Like I said, it's a speculative play.. the company is in a difficult situation. However, the risk/reward ratio is something I'm comfortable with. If 25% dilution leads to a 25% drop in the share price, then that's fine too (I'll still be in the black). It gives them the cash to close one of these design deals hopefully, and if they do that their fortunes change instantly.
There it is, a raise of $6MM. At a fair price too. Let's see how the market responds. Personally, I find it positive.
Like I said, it's speculative, but not a "scam" IMO. I'm sorry for those who have held on over the years are are sitting on losses, but it seems the outcome for this company could be very binary: flop or soar. And we should know that within one year at the most I imagine.
As for timing a new position, that's anyone's guess. If the design work is going well, any dilution from funding may be outweighed by the anticipation of a large deal.
I don't agree. This company is entirely a legitimate outfit with a very impressive team and a real possibility of commercializing a product based on their IP. If the design work they're doing now shows promise, they should easily be able to raise more funds. Yes it will dilute, and yes it's a risky investment, but this company has a real shot at commercial success in 2017. I like the odds, and have invested accordingly. Speculative, but with tremendous upside potential from here IMO.
SwissINSO is getting some love, albeit still with very modest volume. Still, it's nice to see. Maybe one of these weeks we'll see the SEC filings get caught up and finally have a letter from the CEO about commercial progress? I'm surprised they didn't PR the heck out of the Danish school project!
People, this is big big news.
Here's a copy of the PR. Emphasis is mine.
Ideal Power Reports Semiconductor Fabricator Successfully Tested Its B-TRAN Technology
Third Party Testing of First B-TRAN Semiconductor Structures Validate Key Performance Characteristics
AUSTIN, TX--(Marketwired - Apr 18, 2016) - Ideal Power Inc. (NASDAQ: IPWR), a developer of innovative power conversion technologies, reported its semiconductor fabricator successfully tested Bi-Directional Bi-Polar Junction TRANsistor (B-TRAN™) silicon dies and test results validate key characteristics of the semiconductor power switch. The test results can be found in the company's updated B-TRAN White Paper. The results confirm central B-TRAN™ elements and operational modes are consistent with third party device simulations that predict significant performance and efficiency improvements over conventional power switches such as SCRs, IGBTs and MOSFETs.
Ideal Power currently has 12 issued and over 40 patents pending in the United States and abroad related to the B-TRAN™ device, which is a symmetric double-sided structure that presents unique opportunities for high current density operation at high efficiency. B-TRANs have potential uses in a wide range of power conversion and control applications, including very low loss AC power control and in power converters from Ideal Power and other power converter OEMs.
"This validation of key characteristics of the B-TRAN™ technology is a significant step forward in demonstrating B-TRAN's ability to improve energy efficiency across a wide range of products and applications," said Dr. Richard Blanchard, B-TRAN™ co-inventor and holder of over 200 patents primarily related to power semiconductors including the widely used trench MOSFET. "The device has tremendous implications for the power industry."
"These exciting results of the first tested B-TRAN™ structures validate key characteristics of the device and confirm our belief that B-TRANs can be a disruptive new force in many power conversion applications," said Bill Alexander, CTO of Ideal Power and co-inventor of the B-TRAN™. "The predicted extremely low forward voltage drop and fast, low loss switching of the B-TRAN™ are each approximately ten times better than conventional switches. B-TRAN's high current density and native bi-directional capability can lead to very high efficiency power control and conversion at very low cost points. We expect these anticipated efficiency improvements to translate to a substantial cost-performance advantage over current generation power semiconductor devices, which opens a multi-billion dollar market opportunity for the B-TRAN™ and is generating licensing inquiries from power semiconductor companies."
Ideal Power plans to introduce the B-TRAN™ into the rapidly growing power semiconductor market, estimated to be $17 billion in 2015 according to research firm IHS Technology. The next major milestone for commercializing the B-TRAN™ will be testing a fully-packaged device.
Ideal Power believes its new B-TRAN™ technology can potentially address up to 50% of the power semiconductor market as a replacement for older, less efficient power switch technologies such as IGBTs and MOSFETs, as well as the newer gallium nitride (GaN) and silicon carbide (SiC) devices. Potential addressable markets for B-TRAN-based products include very low loss solid-state DC and AC contactors, electric vehicle drivetrains, variable frequency drives, solar photovoltaic inverters, bi-directional energy storage and microgrid power conversion systems, matrix converters and other power conversion products.
Based on third party simulations and testing to date, the Company expects the B-TRAN to deliver 10 to 200 times the cost-performance of current power semiconductor switches, depending on the switch type and configuration, with cost-performance being defined as the combination of device cost and on-state resistance. For a given cost, the B-TRAN™ is expected to have 10 to 200 times lower on-state resistance, while simultaneously having up to 10 times faster switching than other silicon-based switches.
About Ideal Power Inc.
Ideal Power Inc. (NASDAQ: IPWR) has developed a novel, patented power conversion technology called Power Packet Switching Architecture™ (PPSA). PPSA improves the size, cost, efficiency, flexibility and reliability of electronic power converters. PPSA can scale across several large and growing markets, including commercial grid storage, combined solar and storage, microgrids, and electrified vehicle charging. Ideal Power also has a capital-efficient business model that can enable it to address these markets simultaneously. Ideal Power has won multiple grants for its PPSA technology, including a $2.5 million grant from the Department of Energy's Advanced Research Projects Agency - Energy (ARPA-E) program, and market-leading customers are incorporating PPSA as a key component of their systems. For more information, visit www.IdealPower.com.
Safe Harbor Statement
All statements in this release that are not based on historical fact are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Specific forward-looking statements include our comments about expected performance of B-TRAN™ products, potential technical advantages compared to competing technologies, potential markets we could address with our B-TRAN™ technology, and the potential market impact of this technology in these markets. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, whether the patents for our technology provide adequate protection and whether we can be successful in maintaining, enforcing and defending our patents, whether a demand for energy storage products will grow, whether demand for our products, which we believe are disruptive, will develop and whether we can compete successfully with other manufacturers and suppliers of energy conversion products, both now and in the future, as new products are developed and marketed. The B-TRAN™ is a new and novel technology. We may encounter difficulties manufacturing the B-TRAN™ (or having the B-TRAN™ manufactured) in commercial quantities with acceptable margins or at all, and commercially manufactured B-TRAN™ devices may not achieve the technical performance improvements we expect based on preliminary tests conducted to date. There are risks that the device might not achieve market acceptance in these markets. In addition, competitors may offer products based upon competing technologies that outperform the B-TRAN™. The costs of manufacturing, marketing and selling the B-TRAN™ may exceed our expectations so that we may not realize acceptable, or any, profit margins related to B-TRAN™ sales or license revenue. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.
Ideal Power Media Contact:
Mercom Communications
www.mercomcapital.com
Wendy Prabhu
Email Contact
1.512.215.4452
Ideal Power Inc. Investor Relations Contact:
MZ North America
www.mzgroup.us
Matt Hayden
Email Contact
1.949.259.4986
MZ Group
http://www.mzgroup.us/
You left out "revenue". It's kinda the missing thing here.
Let's face it, they may have some decent IP around carbon-based fuel-cells and CC, but they are incapable of getting any commercial traction with either of them.
"bridge financing" implies there's something to bridge to. This financing is more like a plank from the edge of the SS Mantra into thin air and over treacherous waters.
More amazing news out of the RHB-104 Phase IIa study today.
Fist-pounding buy.